NAS:VBLT (Israel)

Vascular Biogenics Ltd

$ 1.33 0.05 (3.91%)
Volume: 36,907 Avg Vol (1m): 117,841
Market Cap $: 47.72 Mil Enterprise Value $: 3.43 Mil
P/E (TTM): 0.00 P/B: 0.95
Earnings Power Value -6.81
Net Current Asset Value 1.07
Tangible Book 1.38
Projected FCF 0
Median P/S Value 0.17
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 5/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 14.19
Cash-To-Debt ranked higher than
73.93% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
VBLT: 14.19
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.35, Med: 10000, Max: 10000
Current: 14.19
0.35
10000
Equity-to-Asset 0.82
Equity-to-Asset ranked higher than
72.21% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
VBLT: 0.82
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.82, Med: 0.86, Max: 0.88
Current: 0.82
0.82
0.88
Debt-to-Equity 0.07
Debt-to-Equity ranked lower than
100.00% of 500 companies
in the Biotechnology industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
VBLT: 0.07
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -1.32, Med: 0.02, Max: 0.07
Current: 0.07
-1.32
0.07
Debt-to-EBITDA -0.20
Debt-to-EBITDA ranked lower than
100.00% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
VBLT: -0.2
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -1.97, Med: -1, Max: -0.04
Current: -0.2
-1.97
-0.04
Piotroski F-Score 2
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -2.12
DISTRESS
GREY
SAFE
Beneish M-Score -6.45
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -554.76%
WACC 15.45%

Profitability & Growth : 2/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -2854.29
Operating Margin ranked lower than
90.78% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
VBLT: -2854.29
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -3625.13, Med: -1850.99, Max: -76.85
Current: -2854.29
-3625.13
-76.85
Net Margin % -2724.02
Net Margin ranked lower than
90.66% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
VBLT: -2724.02
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -3497.09, Med: -1785.11, Max: -73.12
Current: -2724.02
-3497.09
-73.12
ROE % -32.25
ROE ranked higher than
58.04% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
VBLT: -32.25
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -302.23, Med: -41.91, Max: -20.63
Current: -32.25
-302.23
-20.63
ROA % -27.69
ROA ranked higher than
58.39% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
VBLT: -27.69
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -128.42, Med: -38.48, Max: -17.95
Current: -27.69
-128.42
-17.95
ROC (Joel Greenblatt) % -195.67
ROC (Joel Greenblatt) ranked higher than
71.53% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
VBLT: -195.67
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -4348.25, Med: -3163.53, Max: -195.67
Current: -195.67
-4348.25
-195.67
3-Year Total EBITDA Growth Rate -10.80
3-Year EBITDA Growth Rate ranked higher than
90.52% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
VBLT: 5.7
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: 5.7, Med: 9.75, Max: 47.2
Current: 5.7
5.7
47.2
3-Year EPS w/o NRI Growth Rate 5.30
3-Year EPS w/o NRI Growth Rate ranked higher than
89.78% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
VBLT: 5.3
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: 13.25, Max: 50.7
Current: 5.3
0
50.7

» VBLT's 30-Y Financials

Financials (Next Earnings Date: 2019-08-16)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:VBLT

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare OHEL:BIOBV NAS:ALRN TSE:6090 ASX:NOX OTCPK:PMCB OSTO:ASAP NAS:CLSD TSE:4585 LSE:MTPH OTCPK:IGXT NAS:AQB NAS:OPNT LSE:DEST XPAR:ONXEO ROCO:6580 NAS:BVXV NAS:VTGN NAS:PLXP OSTO:MVIR B OSTO:ACE
Traded in other countries
Address 8 HaSatat Street, Modi’in, ISR, 7178106
Vascular Biogenics Ltd is an Israel-based clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of first-in-class treatments for cancer. The lead product candidate of the company is VB-111 which is a gene-based biologic which is being developed for solid tumor indications for recurrent glioblastoma, an aggressive form of brain cancer. The company is also engaged in conducting a program targeting anti-inflammatory diseases, based on the use of Lecinoxoid platform technology. The product brands of the company include VTS, Vascular Targeting Systems, Vbl, Vascular Biogenics And Vascular Therapeutics.

Ratios

Current vs industry vs history
PB Ratio 0.95
PB Ratio ranked higher than
91.16% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
VBLT: 0.95
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0.41, Med: 1.13, Max: 4.44
Current: 0.95
0.41
4.44
PS Ratio 69.99
PS Ratio ranked lower than
92.15% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
VBLT: 69.99
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 2.2, Med: 8.9, Max: 87.37
Current: 69.99
2.2
87.37
EV-to-EBIT -0.19
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
VBLT: -0.19
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -17.1, Med: -0.6, Max: 1.3
Current: -0.19
-17.1
1.3
EV-to-EBITDA -0.19
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
VBLT: -0.19
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -17.4, Med: -0.6, Max: 1.4
Current: -0.19
-17.4
1.4
EV-to-Revenue 5.33
EV-to-Revenue ranked lower than
88.85% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
VBLT: 5.33
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: -48.1, Med: 0.95, Max: 23.8
Current: 5.33
-48.1
23.8
Current Ratio 8.35
Current Ratio ranked higher than
63.78% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
VBLT: 8.35
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 1.5, Med: 9.22, Max: 13.12
Current: 8.35
1.5
13.12
Quick Ratio 8.35
Quick Ratio ranked higher than
64.25% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
VBLT: 8.35
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 1.5, Med: 9.22, Max: 13.12
Current: 8.35
1.5
13.12
Days Payable 2.00
Days Payable ranked lower than
80.04% of 536 companies
in the Biotechnology industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
VBLT: 2
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 2, Med: 2567.91, Max: 3282.85
Current: 2
2
3282.85

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -13.60
3-Year Share Buyback Rate ranked lower than
52.74% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
VBLT: -13.6
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -23.1, Med: -14.05, Max: -13.2
Current: -13.6
-23.1
-13.2

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 0.96
Price-to-Tangible-Book ranked higher than
93.51% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
VBLT: 0.96
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 0.66, Med: 3.28, Max: 68.4
Current: 0.96
0.66
68.4
Price-to-Median-PS-Value 7.82
Price-to-Median-PS-Value ranked higher than
58.41% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
VBLT: 7.82
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0, Med: 0.86, Max: 9.7
Current: 7.82
0
9.7
Earnings Yield (Joel Greenblatt) % -517.75
Earnings Yield (Greenblatt) ranked lower than
73.64% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
VBLT: -517.75
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -3343.3, Med: -27.7, Max: 10206.9
Current: -517.75
-3343.3
10206.9

More Statistics

Revenue (TTM) (Mil) $ 0.64
EPS (TTM) $ -0.5
Beta 2.26
Volatility % 57.96
52-Week Range $ 0.6 - 3.1
Shares Outstanding (Mil) 35.88

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 2
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N